Almirall SA, k'hamphani ea lefats'e ea biopharmaceutical e shebaneng le bophelo bo botle ba letlalo, e phatlalalitse kajeno tlhahiso ea khoebo ea Europe ea Wynzora® cream (50 µg/g calcipotriol le 0.5 mg/g betamethasone as dipropionate), e ntlafalitsoeng bakeng sa kalafo ea lihlooho tse bonolo ho isa ho tse itekanetseng tsa plaque psoriasis batho ba baholo ho kenyeletsa le letlalo la hlooho. Spain, Jeremane le UK ke linaha tsa pele tsa Europe moo tranelate e fumanehang bakeng sa lengolo la ngaka. Ka mor'a ho qalisoa ha lihlooho tsena tse ncha, Almirall e fetoha eona feela k'hamphani ea biopharmaceutical Europe ho fa bakuli ba psoriasis likhetho tse ngata tse koahelang mefuta eohle ea lefu lena, ho tloha lihloohong ho ea ho oral systemics le biologics.
Wynzora® Cream e tsamaisoa ke PAD Technology, mokhoa o mocha oa ho kopanya oli le metsi, e leng se etsang hore e be eona feela calcipotriene le betamethasone dipropionate topical e lumellang ho kopanya metsoako e sebetsang ka har'a tranelate e nang le metsi. Theknoloji e etsa hore ho be le mokhoa o tsitsitseng mme e fana ka boemo bo botle ba polokeho le boiketlo ba mokuli.
Wynzora® e fana ka ts'ebetso e phahameng le ts'ebetso e potlakileng nakong ea beke e le 'ngoe. Liphetho tsa tlhahlobo e kopaneng ea liteko tse peli tsa Phase III li bonts'itse hore tranelate ena ea CAL/BDP PAD e fana ka katleho e phahameng le boleng ba bophelo ba mokuli kalafong ea li-psoriasis ha e bapisoa le sebopeho sa gel ea calcipotriene le betamethasone dipropionate bakeng sa lintlha tsohle tse sebetsang ho kenyelletsa. Katleho ea kalafo ea PGA, mPASI, le PASI1 kamora libeke tse 75 tsa ts'ebeliso ea letsatsi le letsatsi.
Lipatlisiso tsa kliniki li boetse li bontšitse hore, ka mor'a libeke tse robeli tsa phekolo, karolo e kholo haholo ea batho ba tšoaroang ka CAL / BDP PAD-cream ba tlaleha hore psoriasis ha e na phello ho hang bophelong ba bona (DLQI 0 kapa 1) ha e bapisoa le gel ea CAL / BDP. . Kamohelo ea mokuli ea CAL/BDP PAD-cream e ne e bakoa haholo-holo ka taba ea sehlooho e le sebopeho se seng sa mafura se thehiloeng ho theknoloji e ncha ea PAD. Liphetho tse tsoang litekong tsa kliniki tsa Phase III li ile tsa hatisoa ho Journal of the European Academy of Dermatology and Venereology (JEADV).
Psoriasis ke e 'ngoe ea mafu a atileng ka ho fetesisa a letlalo, a amang bonyane batho ba limilione tse 100 lefatšeng ka bophara le hoo e ka bang 1.52% ea baahi ba UK (batho ba hakanyetsoang ho limilione tse 1.01). E ama hampe boleng ba bophelo mme e emela moroalo o moholo bophelong ba letsatsi le letsatsi ba 71% ea bakuli, e amang bophelo bo botle ba maikutlo ba 88% ea batho ba nang le bothata bona. "Lilemong tsa morao tjena re bone lintlafatso tse kholo liphekolong tse fumanehang bakeng sa psoriasis, leha ho le joalo, ho khomarela kalafo ea litlama ho ntse ho le tlase. Ho fihla ha PAD-cream e ncha ea CAL / BDP ke litaba tse babatsehang bakeng sa sechaba sa psoriasis, bao hona joale ba nang le khetho ea phekolo e kopanyang katleho le ts'ireletso ea lisebelisoa tse sebetsang hantle tsa CAL / BDP ka theknoloji e ncha ea koloi bakeng sa mokuli. bonolo,” ho boletse Moprofesa Anthony Bewley, Setsebi sa Dermatologist, UK.
Ho phatlalatsoa ha Wynzora® Cream ho tsoela pele Europe kaofela ka 2022
Almirall o qalile ho bapatsa Wynzora® Cream naheng ea UK, Spain le Jeremane pejana khoeling ena mme o lebelletse ho qala ho sebetsa linaheng tse ling tsa Europe likhoeling tse tlang, hang ha tumello ea ho bapatsa ea naha e se e fanoe. Sehlahisoa sena se fumane tumello ea ho laola Czech Republic, Denmark, France, Germany, Netherlands, Norway, Spain, Sweden, UK, Finland, Portugal, Italy le Ireland ka lebitso la Wynzora®, le lebitso la Winxory® ho la Austria.
"Ho qalisoa ha Wynzora® Cream Europe ke mohato o hatelang pele boitlamo ba rona ba ho fana ka liphekolo tse ncha tse ntlafatsang bophelo ba bakuli ba nang le psoriasis. Hona joale, 73% ea bakuli ha ba khomarele mekhoa ea phekolo ea lihlooho [4]. Ka lebaka la khaello ena e tšoenyang ea ho khomarela liphekolo tse joalo, Almirall o na le bonnete ba hore sehlahisoa sena se secha, se nang le ts'ebetso e netefalitsoeng le sebopeho se bonolo sa mokuli, se tla tšoaea phetoho ka ho ntlafatsa khotsofalo ea bakuli ba psoriasis ka lebaka la sebopeho sa sona se se nang mafura, "ho boletse joalo. Gianfranco Nazzi, Ofisiri e ka Sehloohong ea Phethahatso ea Almirall.
"Ho thakholoa ha Wynzora ® Cream linaheng tsa Europe ho tšoaea ketsahalo e 'ngoe ea bohlokoa ho phatlalatsoeng ha sehlahisoa lefatšeng ka bophara. Krime ena ke ponahatso ea thepa ea bohlokoa ea mokhoa oa ho qapa le ho tsamaisa lithethefatsi PAD Technology. E hlophisitsoe ka tabatabelo ea ho fana ka ts'ebetso e potlakileng le ts'ebetso e phahameng, boemo bo botle ba polokeho le boiketlo bo phahameng le khotsofalo ho bakuli lits'ebetsong tsa letsatsi le letsatsi ka sehlahisoa se le seng. Re lumela hore ho nolofatsa le ho khomarela melao ke eona ntho e ncha e sebetsang,” ho boletse Jesper J. Lange, CEO oa MC2 Therapeutics, mohlahisi oa PAD Technology.
Ka Hlakola 2021, Almirall le MC2 Therapeutics li ile tsa kena tumellanong ea leano moo MC2 Therapeutics e ileng ea fa Almirall litokelo tse khethehileng tsa Europe tsa ho rekisa Wynzora® Cream bakeng sa kalafo ea plaque psoriasis. Likhamphani ka bobeli li phatlalalitse katleho e atlehileng ea ts'ebetso ea decentralized ka July 2021. Cream e boetse e rekisoa US ke k'hamphani e 'ngoe.
